Cancers often upregulate the key cholesterol uptake molecules such as NPC1, NPC1-like 1 protein (NPC1L1), LDLR, SR-B1, and proprotein convertase subtilisin/kexin like 9 (PCSK9) making them the most logical targets of possible pharmaceutical interventions. The gene discussed is LDLR; the disease is cancer.